Related references
Note: Only part of the references are listed.Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
B. Escudier et al.
ANNALS OF ONCOLOGY (2019)
Syntaxin 6: A novel predictive and prognostic biomarker in papillary renal cell carcinoma
Taylor C. Peak et al.
SCIENTIFIC REPORTS (2019)
The Prognostic Value of Cancer Stem Cell Markers (Notch1, ALDH1, and CD44) in Primary Colorectal Carcinoma
Salem Y. Mohamed et al.
JOURNAL OF GASTROINTESTINAL CANCER (2019)
IL-6 is involved in malignancy and doxorubicin sensitivity of renal carcinoma cells
Yanqiang Chen et al.
CELL ADHESION & MIGRATION (2018)
Characterization of Clinical Cases of Advanced Papillary Renal Cell Carcinoma via Comprehensive Genomic Profiling
Sumanta K. Pal et al.
EUROPEAN UROLOGY (2018)
Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2α Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell Carcinoma
Kevin D. Courtney et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Exosomal microRNA-32-5p induces multidrug resistance in hepatocellular carcinoma via the PI3K/Akt pathway
Xiao Fu et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2018)
Modulating ATP binding cassette transporters in papillary renal cell carcinoma type 2 enhances its response to targeted molecular therapy
Rola M. Saleeb et al.
MOLECULAR ONCOLOGY (2018)
Targeting loss of the Hippo signaling pathway in NF2-deficient papillary kidney cancers
Carole Sourbier et al.
Oncotarget (2018)
Cancer stem cell markers ALDH1 and CD44+/CD24- phenotype and their prognosis impact in invasive ductal carcinoma
Iris Rabinovich et al.
EUROPEAN JOURNAL OF HISTOCHEMISTRY (2018)
Characterisation of the Morphological, Functional and Molecular Changes in Sunitinib-Resistant Renal Cell Carcinoma Cells
Hossam Kamli et al.
JOURNAL OF KIDNEY CANCER AND VHL (2018)
Kidney Cancer, Version 2.2017 Clinical Practice Guidelines in Oncology
Robert J. Motzer et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2017)
EMT, CSCs, and drug resistance: the mechanistic link and clinical implications
Tsukasa Shibue et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Resistance to mTORC1 Inhibitors in Cancer Therapy: From Kinase Mutations to Intratumoral Heterogeneity of Kinase Activity
Seraina Faes et al.
OXIDATIVE MEDICINE AND CELLULAR LONGEVITY (2017)
Analysis of renal cancer cell lines from two major resources enables genomics-guided cell line selection
Rileen Sinha et al.
NATURE COMMUNICATIONS (2017)
Hypoxic 3D in vitro culture models reveal distinct resistance processes to TKIs in renal cancer cells
Zofia F. Bielecka et al.
CELL AND BIOSCIENCE (2017)
Correlation of ALDH1 and Notch3 Expression: Clinical implication in Ovarian Carcinomas
Mi Joung Kim et al.
JOURNAL OF CANCER (2017)
PHGDH as a Key Enzyme for Serine Biosynthesis in HIF2α-Targeting Therapy for Renal Cell Carcinoma
Hirofumi Yoshino et al.
CANCER RESEARCH (2017)
Functional significance of CD105-positive cells in papillary renal cell carcinoma
Damian Matak et al.
BMC CANCER (2017)
Molecular mechanism mediating cytotoxic activity of axitinib in sunitinib-resistant human renal cell carcinoma cells
A. Miyazaki et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2016)
miRTarBase 2016: updates to the experimentally validated miRNA-target interactions database
Chih-Hung Chou et al.
NUCLEIC ACIDS RESEARCH (2016)
Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
B. Escudier et al.
ANNALS OF ONCOLOGY (2016)
Decreased apoptosis repressor with caspase recruitment domain confers resistance to sunitinib in renal cell carcinoma through alternate angiogenesis pathways
Glenda C. Gobe et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2016)
GSK-3 directly regulates phospho-4EBP1 in renal cell carcinoma cell-line: an intrinsic subcellular mechanism for resistance to mTORC1 inhibition
Hiromi Ito et al.
BMC CANCER (2016)
Elevated RET expression enhances EGFR activation and mediates EGFR inhibitor resistance in head and neck squamous cell carcinoma
Chengzhong Lin et al.
CANCER LETTERS (2016)
A Randomised Phase 2 Study of AZD2014 Versus Everolimus in Patients with VEGF-Refractory Metastatic Clear Cell Renal Cancer
Thomas Powles et al.
EUROPEAN UROLOGY (2016)
The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours
Holger Moch et al.
EUROPEAN UROLOGY (2016)
Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma
Thomas Powles et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Melatonin inhibits MMP-9 transactivation and renal cell carcinoma metastasis by suppressing Akt-MAPKs pathway and NF-B DNA-binding activity
Yung-Wei Lin et al.
JOURNAL OF PINEAL RESEARCH (2016)
Fibroblast Growth Factor Receptor-Dependent and -Independent Paracrine Signaling by Sunitinib-Resistant Renal Cell Carcinoma
Tram Anh Tran et al.
MOLECULAR AND CELLULAR BIOLOGY (2016)
Choosing the right cell line for renal cell cancer research
Klaudia K. Brodaczewska et al.
MOLECULAR CANCER (2016)
Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma
W. Marston Linehan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
A Phase Ib Study of BEZ235, a Dual Inhibitor of Phosphatidylinositol 3-Kinase (PI3K) and Mammalian Target of Rapamycin (mTOR), in Patients With Advanced Renal Cell Carcinoma
Maria I. Carlo et al.
ONCOLOGIST (2016)
Comparative Gene Expression Profiling of Primary and Metastatic Renal Cell Carcinoma Stem Cell-Like Cancer Cells
Mohammed I. Khan et al.
PLOS ONE (2016)
Assessment of early therapeutic response to sorafenib in renal cell carcinoma xenografts by dynamic contrast-enhanced and diffusion-weighted MR imaging
T. Y. Jeon et al.
BRITISH JOURNAL OF RADIOLOGY (2015)
The MET Inhibitor AZD6094 (Savolitinib, HMPL-504) Induces Regression in Papillary Renal Cell Carcinoma Patient-Derived Xenograft Models
Alwin G. Schuller et al.
CLINICAL CANCER RESEARCH (2015)
SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer
Christian Eichelberg et al.
EUROPEAN UROLOGY (2015)
Impact of O6-methylguanine-DNA methyltransferase expression on the drug resistance of clear cell renal cell carcinoma
Nan Ge et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2015)
The PI3K/AKT Pathway and Renal Cell Carcinoma
Huifang Guo et al.
JOURNAL OF GENETICS AND GENOMICS (2015)
Low expression of phosphatase and tensin homolog in clear-cell renal cell carcinoma contributes to chemoresistance through activating the Akt/HDM2 signaling pathway
Jun Chen et al.
MOLECULAR MEDICINE REPORTS (2015)
RLIP76 Targeted Therapy for Kidney Cancer
Sharad S. Singhal et al.
PHARMACEUTICAL RESEARCH (2015)
Glycogen synthase kinase-3 (GSK3): Regulation, actions, and diseases
Eleonore Beurel et al.
PHARMACOLOGY & THERAPEUTICS (2015)
Heparanase released from mesenchymal stem cells activates integrin beta1/HIF-2alpha/Flk-1 signaling and promotes endothelial cell migration and angiogenesis
Xinyang Hu et al.
STEM CELLS (2015)
miR-124 represses FZD5 to attenuate P-glycoprotein-mediated chemo-resistance in renal cell carcinoma
Qing-Zhi Long et al.
TUMOR BIOLOGY (2015)
p21-activated kinase 1 determines stem-like phenotype and sunitinib resistance via NF-κB/IL-6 activation in renal cell carcinoma
Y. Zhu et al.
CELL DEATH & DISEASE (2015)
Cross-resistance to clinically used tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib
Kristy J. Gotink et al.
CELLULAR ONCOLOGY (2015)
Enhanced sensitivity to sorafenib by inhibition of Akt1 expression in human renal cell carcinoma ACHN cells both in vitro and in vivo
Hiromoto Tei et al.
HUMAN CELL (2015)
Epithelial to mesenchymal transition is associated with rapamycin resistance
Ashley M. Holder et al.
ONCOTARGET (2015)
BMP-2 inhibits tumor-initiating ability in human renal cancer stem cells and induces bone formation
Lin Wang et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2015)
MiR-124 represses vasculogenic mimicry and cell motility by targeting amotL1 in cervical cancer cells
Hai-Ying Wan et al.
CANCER LETTERS (2014)
FoxO Transcription Factors Promote AKT Ser473 Phosphorylation and Renal Tumor Growth in Response to Pharmacologic Inhibition of the PI3K-AKT Pathway
Aifu Lin et al.
CANCER RESEARCH (2014)
Sphingosine Kinase-1 Activation Causes Acquired Resistance Against Sunitinib in Renal Cell Carcinoma Cells
Hui Gao et al.
CELL BIOCHEMISTRY AND BIOPHYSICS (2014)
Conversion of differentiated cancer cells into cancer stem-like cells in a glioblastoma model after primary chemotherapy
B. Auffinger et al.
CELL DEATH AND DIFFERENTIATION (2014)
Characterization of mechanism involved in acquired resistance to sorafenib in a mouse renal cell cancer RenCa model
K. Harada et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2014)
ABC Transporters in Multidrug Resistance and Pharmacokinetics, and Strategies for Drug Development
Young Hee Choi et al.
CURRENT PHARMACEUTICAL DESIGN (2014)
Synergistic Signaling of Tumor Cell Invasiveness by Hepatocyte Growth Factor and Hypoxia
Young H. Lee et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2014)
The cross-talk between canonical and non-canonical Wnt-dependent pathways regulates P-glycoprotein expression in human blood-brain barrier cells
Martha L. Pinzon-Daza et al.
JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM (2014)
The expression and role of tyrosine kinase ETK/BMX in renal cell carcinoma
Jintao Zhuang et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2014)
ALDH1 activity identifies tumor-initiating cells and links to chromosomal instability signatures in multiple myeloma
W. Zhou et al.
LEUKEMIA (2014)
Discovery and saturation analysis of cancer genes across 21 tumour types
Michael S. Lawrence et al.
NATURE (2014)
Identification of Tissue microRNAs Predictive of Sunitinib Activity in Patients with Metastatic Renal Cell Carcinoma
Celia Prior et al.
PLOS ONE (2014)
Kidney cancer cells secrete IL-8 to activate Akt and promote migration of mesenchymal stem cells
Bi Liang-kuan et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2014)
The miR-124-Prolyl Hydroxylase P4HA1-MMP1 axis plays a critical role in prostate cancer progression
Balabhadrapatruni V. S. K. Chakravarthi et al.
ONCOTARGET (2014)
GSK-3 as potential target for therapeutic irvention in cancer
James A. McCubrey et al.
ONCOTARGET (2014)
Low expression levels of microRNA-124-5p correlated with poor prognosis in colorectal cancer via targeting of SMC4
Takafumi Jinushi et al.
CANCER MEDICINE (2014)
Acquired resistance to sunitinib in human renal cell carcinoma cells is mediated by constitutive activation of signal transduction pathways associated with tumour cell proliferation
Iori Sakai et al.
BJU INTERNATIONAL (2013)
Acquired resistance to temsirolimus in human renal cell carcinoma cells is mediated by the constitutive activation of signal transduction pathways through mTORC2
K. Harada et al.
BRITISH JOURNAL OF CANCER (2013)
Hsa-mir-124-3 CpG island methylation is associated with advanced tumours and disease recurrence of patients with clear cell renal cell carcinoma
K. Gebauer et al.
BRITISH JOURNAL OF CANCER (2013)
Angiogenic and signalling proteins correlate with sensitivity to sequential treatment in renal cell cancer
R. Rosa et al.
BRITISH JOURNAL OF CANCER (2013)
Clinical outcomes in patients receiving three lines of targeted therapy for metastatic renal cell carcinoma: Results from a large patient cohort
Roberto Iacovelli et al.
EUROPEAN JOURNAL OF CANCER (2013)
Ovatodiolide Targets β-Catenin Signaling in Suppressing Tumorigenesis and Overcoming Drug Resistance in Renal Cell Carcinoma
Jar-Yi Ho et al.
EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE (2013)
Inhibition of MMP-9 using a pyrrole-imidazole polyamide reduces cell invasion in renal cell carcinoma
Aya Sato et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2013)
Initial Clinical Sensitivity and Acquired Resistance to MET Inhibition in MET-Mutated Papillary Renal Cell Carcinoma
Jennifer R. Diamond et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
DIANA-microT web server v5.0: service integration into miRNA functional analysis workflows
Maria D. Paraskevopoulou et al.
NUCLEIC ACIDS RESEARCH (2013)
Aldehyde Dehydrogenase 1 Identifies Cells with Cancer Stem Cell-Like Properties in a Human Renal Cell Carcinoma Cell Line
Kosuke Ueda et al.
PLOS ONE (2013)
GSK-3 inhibition in vitro and in vivo enhances antitumor effect of sorafenib in renal cell carcinoma (RCC)
Hisashi Kawazoe et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2012)
Wnt/β-catenin pathway regulates ABCB1 transcription in chronic myeloid leukemia
Stephany Correa et al.
BMC CANCER (2012)
Mechanisms of resistance to vascular endothelial growth factor blockade
Shaad E. Abdullah et al.
CANCER (2012)
Incidence and long-term prognosis of papillary compared to clear cell renal cell carcinoma - A multicentre study
Sandra Steffens et al.
EUROPEAN JOURNAL OF CANCER (2012)
Genetic basis of kidney cancer: Role of genomics for the development of disease-based therapeutics
W. Marston Linehan
GENOME RESEARCH (2012)
Autocrine VEGF-VEGFR2-Neuropilin-1 signaling promotes glioma stem-like cell viability and tumor growth
Petra Hamerlik et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2012)
DIANA miRPath v.2.0: investigating the combinatorial effect of microRNAs in pathways
Ioannis S. Vlachos et al.
NUCLEIC ACIDS RESEARCH (2012)
Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia
Sarah J. Conley et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Tyrosine kinase expression profile in clear cell renal cell carcinoma
Turang E. Behbahani et al.
WORLD JOURNAL OF UROLOGY (2012)
A novel fumarate hydratase-deficient HLRCC kidney cancer cell line, UOK268: a model of the Warburg effect in cancer
Youfeng Yang et al.
CANCER GENETICS (2012)
Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma (RCC): an Italian multicentre retrospective analysis of 189 patient cases
Camillo Porta et al.
BJU INTERNATIONAL (2011)
GSK1120212 (JTP-74057) Is an Inhibitor of MEK Activity and Activation with Favorable Pharmacokinetic Properties for Sustained In Vivo Pathway Inhibition
Aidan G. Gilmartin et al.
CLINICAL CANCER RESEARCH (2011)
Interplay Between pVHL and mTORC1 Pathways in Clear-Cell Renal Cell Carcinoma
Blanka Kucejova et al.
MOLECULAR CANCER RESEARCH (2011)
GDC-0980 Is a Novel Class I PI3K/mTOR Kinase Inhibitor with Robust Activity in Cancer Models Driven by the PI3K Pathway
Jeffrey J. Wallin et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Chromosomal amplification of leucine-rich repeat kinase-2 (LRRK2) is required for oncogenic MET signaling in papillary renal and thyroid carcinomas
Brendan D. Looyenga et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Mechanisms of mTOR inhibitor resistance in cancer therapy
Jennifer S. Carew et al.
TARGETED ONCOLOGY (2011)
UOK 262 cell line, fumarate hydratase deficient (FH-/FH-) hereditary leiomyomatosis renal cell carcinoma: in vitro and in vivo model of an aberrant energy metabolic pathway in human cancer
Youfeng Yang et al.
CANCER GENETICS AND CYTOGENETICS (2010)
Interleukin-8 Mediates Resistance to Antiangiogenic Agent Sunitinib in Renal Cell Carcinoma
Dan Huang et al.
CANCER RESEARCH (2010)
Sunitinib Acts Primarily on Tumor Endothelium rather than Tumor Cells to Inhibit the Growth of Renal Cell Carcinoma
Dan Huang et al.
CANCER RESEARCH (2010)
The Efficacy of the Novel Dual PI3-Kinase/mTOR Inhibitor NVP-BEZ235 Compared with Rapamycin in Renal Cell Carcinoma (Publication with Expression of Concern. See vol. 25, pg. 4194, 2019)
Daniel C. Cho et al.
CLINICAL CANCER RESEARCH (2010)
The genetic basis of kidney cancer: a metabolic disease
W. Marston Linehan et al.
NATURE REVIEWS UROLOGY (2010)
Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy
C. A. Sparks et al.
ONCOGENE (2010)
Effects of HIF-1 alpha and HIF2 alpha on Growth andMetabolism of Clear-Cell Renal Cell Carcinoma 786-0 Xenografts
Swethajit Biswas et al.
JOURNAL OF ONCOLOGY (2010)
Sunitinib A Multitargeted Receptor Tyrosine Kinase Inhibitor in the Era of Molecular Cancer Therapies
Georgios S. Papaetis et al.
BIODRUGS (2009)
Glycogen synthase kinase-3: a new therapeutic target in renal cell carcinoma
V. Bilim et al.
BRITISH JOURNAL OF CANCER (2009)
RLIP76: A Target for Kidney Cancer Therapy
Sharad S. Singhal et al.
CANCER RESEARCH (2009)
HAF The new player in oxygen-independent HIF-1 alpha degradation
Mei Yee Koh et al.
CELL CYCLE (2009)
Increased activated Akt expression in renal cell carcinomas and prognosis
Martina Hager et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2009)
Hypoxia inducible factor-1α correlates with vascular endothelial growth factor A and C indicating worse prognosis in clear cell renal cell carcinoma
Gordana Orevic et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2009)
Aldehyde Dehydrogenase 1 Is a Tumor Stem Cell-Associated Marker in Lung Cancer
Feng Jiang et al.
MOLECULAR CANCER RESEARCH (2009)
Expression of multidrug resistance markers ABCB1 (MDR-1/P-gp) and ABCC1 (MRP-1) in renal cell carcinoma
Naomi Walsh et al.
BMC Urology (2009)
Role of MicroRNA miR-27a and miR-451 in the regulation of MDR1/P-glycoprotein expression in human cancer cells
Hua Zhu et al.
BIOCHEMICAL PHARMACOLOGY (2008)
Antitumor effects of a combination of interferon-alpha and sorafenib oil human renal carcinoma cell lines
Shiro Tochizawa et al.
BIOMEDICAL RESEARCH-TOKYO (2008)
MTORCI inhibitors: is temsirolimus in renal cancer telling us how they really work?
C. Le Tourneau et al.
BRITISH JOURNAL OF CANCER (2008)
In vivo validation of PAX2 as a target for renal cancer therapy
Pierre-Alain Hueber et al.
CANCER LETTERS (2008)
Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase
Ji Wu et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
Modulation of p21-activated kinase 1 alters the behavior of renal cell carcinoma
Gerald C. O'Sullivan et al.
INTERNATIONAL JOURNAL OF CANCER (2007)
Regression of lung and colon cancer xenografts by depleting or inhibiting RLIP76 (Ral-binding protein 1)
Sharad S. Singhal et al.
CANCER RESEARCH (2007)
HIF-2α promotes hypoxic cell proliferation by enhancing c-Myc transcriptional activity
John D. Gordan et al.
CANCER CELL (2007)
Detection of DNA copy number changes and oncogenic signaling abnormalities from gene expression data reveals MYC activation in high-grade papillary renal cell carcinoma
Kyle A. Furge et al.
CANCER RESEARCH (2007)
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
Robert J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Renal cancer cells lacking hypoxia inducible factor (HIF)-1 alpha expression maintain vascular endothelial growth factor expression through HIF-2 alpha
Toshiaki Shinojima et al.
CARCINOGENESIS (2007)
PAX2 inactivation enhances cisplatin-induced apoptosis in renal carcinoma cells
PA Hueber et al.
KIDNEY INTERNATIONAL (2006)
Regression of melanoma in a murine model by RLIP76 depletion
SS Singhal et al.
CANCER RESEARCH (2006)
Small molecules that reactivate p53 in renal cell carcinoma reveal a NF-κB-dependent mechanism of p53 suppression in tumors
KV Gurova et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006
CR Yu et al.
ONCOGENE (2005)
Histologic predictors of renal cell carcinoma response to interleukin-2-based therapy
MP Upton et al.
JOURNAL OF IMMUNOTHERAPY (2005)
Characterization of cells with a high aldehyde dehydrogenase activity from cord blood and acute myeloid leukemia samples
DJ Pearce et al.
STEM CELLS (2005)
History of the development of the classification of renal cell neoplasia
B Delahunt et al.
CLINICS IN LABORATORY MEDICINE (2005)
Prognostic value of histologic subtypes in renal cell carcinoma:: A multicenter experience
JJ Patard et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
High frequency of mutations of the PIK3CA gene in human cancers
Y Samuels et al.
SCIENCE (2004)
PI 3-kinase, Akt and cell survival
J Downward
SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY (2004)
Inhibition of both the extrinsic and intrinsic death pathways through nonhomotypic death-fold interactions
YJ Nam et al.
MOLECULAR CELL (2004)
The role of PTEN and its signalling pathways, including AKT, in breast cancer; an assessment of relationships with other prognostic factors and with outcome
AR Panigrahi et al.
JOURNAL OF PATHOLOGY (2004)
Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418
R Bhat et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
GSK-3: tricks of the trade for a multi-tasking kinase
BW Doble et al.
JOURNAL OF CELL SCIENCE (2003)
Cell surface receptors activate p21-activated kinase 1 via multiple Ras and PI3-kinase-dependent pathways
RE Menard et al.
CELLULAR SIGNALLING (2003)
Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control
R Loewith et al.
MOLECULAR CELL (2002)
Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology
RJ Motzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Prognostic impact of histologic Subtyping of adult renal epithelial neoplasms - An experience of 405 cases
MB Amin et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2002)
STAT3, but not ERKs, mediates the IL-6-induced proliferation of renal cancer cells, ACHN and 769P
A Horiguchi et al.
KIDNEY INTERNATIONAL (2002)
Over expression of inhibitor of caspase 3 activated deoxyribonuclease in human renal cell carcinoma cells enhances their resistance to cytotoxic chemotherapy in vivo
S Hara et al.
JOURNAL OF UROLOGY (2001)
HSV-tk gene therapy for human renal cell carcinoma in nude mice
KJ Pulkkanen et al.
CANCER GENE THERAPY (2001)
Molecular cytogenetic analysis of 17 renal cancer cell lines: Increased copy number at 5q31-33 in cell lines from nonpapillary carcinomas
ZQ Yang et al.
JAPANESE JOURNAL OF CANCER RESEARCH (2000)
CROP/Luc7A, a novel serine/arginine-rich nuclear protein, isolated from cisplatin-resistant cell line
Y Nishii et al.
FEBS LETTERS (2000)
Share Paper
